CAR T-cell therapy targeting TAG72 for recurrent epithelial ovarian cancer
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer
This trial tries a CAR T‑cell treatment that targets the TAG72 protein for people with recurrent epithelial ovarian cancer, given directly into the abdomen.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11336746 on NIH RePORTER |
What this research studies
If you join, doctors will collect your T cells, modify them in the lab to recognize the TAG72 protein on tumor cells, expand them, and deliver the engineered cells into your peritoneal (abdominal) space. This is an early-phase (Phase 1) effort focused on safety, finding a tolerable dose, and seeing initial signs of activity against peritoneal metastases and ascites. The team developed the TAG72 CAR at City of Hope and found encouraging results in laboratory and animal tests, and they plan regional (intraperitoneal) delivery to improve tumor access. You will be closely monitored for side effects and for any tumor response over follow-up visits.
Who could benefit from this research
Good fit: Adults with recurrent epithelial ovarian cancer whose tumors express TAG72 and who are medically fit for a phase 1 cellular therapy at City of Hope would be most suitable.
Not a fit: Patients whose tumors lack TAG72 expression, who have uncontrolled infections or serious organ dysfunction, or who are too frail for intensive treatment may not benefit or be eligible.
Why it matters
Potential benefit: If successful, this approach could reduce abdominal tumor burden and control peritoneal spread for people with recurrent ovarian cancer who have few other options.
How similar studies have performed: CAR T therapies have been highly successful in some blood cancers but have had limited results in solid tumors, so this TAG72-targeted, intraperitoneal strategy is novel and early-stage.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Rodriguez-Rodriguez, Lorna — Beckman Research Institute/city of Hope
- Study coordinator: Rodriguez-Rodriguez, Lorna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.